Of the seismic shifts that have taken place in the use of health economic studies over the past decade in the UK, none has had a greater impact than the establishment of the National Institute for Health and Clinical Excellence (NICE) and Scottish Medicines Consortium (SMC). Healthcare manufacturers are now focused, from the very first ventures into clinical development, on the need for their products to be cost-effective. Without data to back up such claims, international agencies, such as NICE and the SMC, have the power to make or break a technology’s success in a particular country. The international requirement for health technology appraisals has placed health economics in the mainstream, near the top of every organisational priority list.
CATALYST undertakes health technology appraisals, which in the past have resulted in successful submissions to many agencies including SMC, NICE and the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia.